Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 2 August 2023, 21:38 HKT/SGT
Share:
Kingworld Medicines Expects 1H Profit Increased By 35%-40%
Demonstrating Strong Business Performance and Competitive Strengths

HONG KONG, Aug 2, 2023 - (ACN Newswire) - Kingworld Medicines Group ("Kingworld Medicines" or the "Group", stock code: 01110.HK), a leading healthcare distribution company, announced a projected rise in profit for the first half of the fiscal year. Based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ending June 30, 2023, the Group anticipates a profit surge ranging from approximately 35% to 40% for the period, compared to the same period last year.

The Board attributes this profit increase to increased revenue and gross profit stemming from the distribution of imported branded pharmaceutical and healthcare products in China, with growth rates reaching approximately 30% to 35% and 15% to 20%, respectively. Additionally, the Group's share of profit from a joint venture saw a boost of approximately 55% to 60% compared to the same period last year. This surge is attributed to the market recovery after the COVID-19 pandemic control measures.

Kingworld Medicines is a company specializing in the distribution of imported branded pharmaceutical and healthcare products in China. The Group adeptly navigated post-pandemic market changes, propelling business expansion by leveraging its industry strengths.

Mr. Zhao Lisheng, Chairman of the Board of Kingworld Medicines Group, commented: "The Group's profit increase was mainly due to market recovery and the Group's employees' unremitting efforts, which adapted post-pandemic. The Group's strengths lie in its strong capabilities in distributing pharmaceutical and healthcare products and its acute insights into the market. Besides, the Group has achieved long-term steady growth by continuously improving efficiency and expanding its business."

Looking ahead, Kingworld Medicines Group will continue to focus on increasing market share, expanding business coverage, and improving efficiency to further enhance the company's profitability and market competitiveness.



Topic: Press release summary Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence  
May 15, 2026 22:20 HKT/SGT
NEC completes construction of approximately 2,250 km EMCS submarine cable linking Pacific island nations  
Friday, May 15, 2026 4:36:00 PM
Fujitsu and Science Tokyo launch joint research hub for quantum hardware advancement and talent development  
Friday, May 15, 2026 4:12:00 PM
Fujitsu and IBM Japan formalize collaboration in healthcare sector  
Friday, May 15, 2026 3:42:00 PM
Toyota Launches All-New Land Cruiser "FJ" Series in Japan  
Friday, May 15, 2026 2:24:00 PM
Mitsubishi Motors Signs Memorandum of Understanding with FPT Japan Holdings to Study Collaboration in Software and Digital Domain  
Friday, May 15, 2026 2:10:00 PM
Your Go-To Travel Checklist for Smarter, Reward-Focused Travel Planning  
May 15, 2026 14:00 HKT/SGT
NEC Launches Orbital Transfer Vehicle Development Project Aiming for Asia's First Vehicle Deployment through JAXA's Space Strategy Fund Program  
Friday, May 15, 2026 1:55:00 PM
Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program  
May 15, 2026 07:00 HKT/SGT
JCB and Discover(R) Network Mark 20 Years of Collaboration  
Thursday, May 14, 2026 10:00:00 PM
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: